Humacyte, Inc.
HUMA$453M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaDURHAM
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Oct 15, 2026
31wMarket Overview
Stock performance and key metrics
HUMA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Human Acellular Vessel (HAV)
Renal Failure
Acellular Tissue Engineered Vessel (ATEV)
End Stage Renal Disease (ESRD)
HAV
Renal Failure
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Human Acellular Vessel (HAV) | Phase 3 | Renal Failure | - | - |
Acellular Tissue Engineered Vessel (ATEV) | Phase 3 | End Stage Renal Disease (ESRD) | - | - |
HAV | Phase 2 | Renal Failure | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply